Literature DB >> 19455402

Chitotriosidase plasma activity in nephropathic cystinosis.

A Xaidara1, E M Karavitakis, K Kosma, F Emma, E Dimitriou, H Michelakakis.   

Abstract

Chitotriosidase is a fully active chitinase produced and secreted by activated phagocytes. Plasma chitotriosidase activity is a well-established marker of total disease burden in Gaucher disease that has proved useful in monitoring the response to both enzyme replacement and substrate reduction therapies in patients with Gaucher disease. Increased chitotriosidase plasma activity has also been observed in several other lysosomal and non lysosomal disorders. Cystinosis, a rare multisystemic lysosomal storage disease, is characterized by the intralysosomal accumulation of free cystine in many cell types including phagocytes. We here report on plasma chitotriosidase activity in a child with nephropathic cystinosis. Increased plasma chitotriosidase activity (481 nmol/h per ml; normal range 0-150 units) was found on diagnosis and prior to the initiation of oral cysteamine (Cystagon) treatment. Serial estimations of plasma chitotriosidase activity showed that it correlated with leukocyte cystine content and decreased to 100 nmol/h per ml following 14 months' treatment. This novel observation suggests that cystinosis should be included in the differential diagnosis of disorders associated with increased plasma chitotriosidase activity. Furthermore, it suggests that serial estimations of plasma chitotriosidase activity could be of value in monitoring the response to oral cysteamine treatment in cystinosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455402     DOI: 10.1007/s10545-009-1118-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  12 in total

Review 1.  Cystinosis: from gene to disease.

Authors:  Vasiliki Kalatzis; Corinne Antignac
Journal:  Nephrol Dial Transplant       Date:  2002-11       Impact factor: 5.992

Review 2.  Cystinosis.

Authors:  William A Gahl; Jess G Thoene; Jerry A Schneider
Journal:  N Engl J Med       Date:  2002-07-11       Impact factor: 91.245

Review 3.  Clinically relevant therapeutic endpoints in type I Gaucher disease.

Authors:  C E Hollak; M Maas; J M Aerts
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

4.  Evaluation of three biochemical markers in the monitoring of Gaucher disease.

Authors:  A Vellodi; Y Foo; T J Cole
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  Chitotriosidase in neonates with fungal and bacterial infections.

Authors:  I Labadaridis; E Dimitriou; M Theodorakis; G Kafalidis; A Velegraki; H Michelakakis
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-11       Impact factor: 5.747

Review 6.  Chitotriosidase: the yin and yang.

Authors:  L Malaguarnera
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

7.  Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine.

Authors:  M Broyer; M J Tête; G Guest; J P Berthélémé; F Labrousse; M Poisson
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 8.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

9.  Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.

Authors:  William A Gahl; Joan Z Balog; Robert Kleta
Journal:  Ann Intern Med       Date:  2007-08-21       Impact factor: 25.391

10.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more
  2 in total

Review 1.  Novel techniques and newer markers for the evaluation of "proximal tubular dysfunction".

Authors:  Michael Ludwig; Sidharth K Sethi
Journal:  Int Urol Nephrol       Date:  2011-03-01       Impact factor: 2.370

2.  Clinical utility of chitotriosidase enzyme activity in nephropathic cystinosis.

Authors:  Mohamed A Elmonem; Samuel H Makar; Lambertus van den Heuvel; Hanan Abdelaziz; Safaa M Abdelrahman; Xavier Bossuyt; Mirian C Janssen; Elisabeth Am Cornelissen; Dirk J Lefeber; Leo Ab Joosten; Marwa M Nabhan; Fanny O Arcolino; Fayza A Hassan; Héloïse P Gaide Chevronnay; Neveen A Soliman; Elena Levtchenko
Journal:  Orphanet J Rare Dis       Date:  2014-11-19       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.